Webinar replay
Biopharma Dealmaking in 2022: Trends & Forecasts
Download the Biopharma Dealmaking eBook now
2021 was a busy year in biopharma dealmaking. There were billion-dollar deals, a flood of funding, increased early-stage partnering, and new therapeutic areas and platforms coming online. Now, armed with record amounts of cash and funding, 2022 is poised to be another remarkable year for life science companies in general and partnering specifically.
Join Chris Dokomajilar, CEO at DealForma, and Echo Zhang, Product Strategy Director at Inova, as they discuss:
- Partnering and dealmaking trends in 2021
- What lies ahead in 2022
Please complete the form below
All fields marked with a * are required.
By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.
personal data by Inova as detailed in the Privacy Statement.



Preview eBook
Download the Biopharma Dealmaking in 2022 eBook:
- 2021 Deal Numbers: Number of Deals Across Therapeutics and Platforms.
- Asset Types and Progress: Large Cap Biopharma Dealmaking Heading into 2022.
- Healthcare and Life Sciences Venture: Venture Totals into Healthcare and Life Sciences by Subsector.

About Inova
Inova accelerates partnering for the future of medicine.
Our cloud-based solutions help life science companies manage
their biopharma opportunities more efficiently. They find all their
partnering information in one place, track their deals and alliances
easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from
the 20 biggest biopharma events automatically available in Inova,
providing our users with always up-to-date company and contact
information. Over 150 life science companies, including 50% of the
top 50 pharmaceutical companies and many midsize pharma and
innovative biotechs already use Inova.